NF2 and mesothelioma: However, the majority of known TEAD inhibitors only show antiproliferative activities in a few cancer cell lines, such as NF2-mutant mesothelioma, and detailed analysis of TEAD palmitoylation inhibitors in a broad range of YAP-dependent cancer models is still lacking.